Unlock the power of liquid biopsy with the OncoSeek cfDNA extraction kit
Unlock the power of liquid biopsy with the OncoSeek cfDNA extraction kit
Isolate high-yield RNA from FFPE blocks consistently
Isolate high-yield RNA from FFPE blocks consistently
Isolate high-quality cfDNA with high recovery and minimal genomic DNA contamination.
Isolate high-quality cfDNA with high recovery and minimal genomic DNA contamination.
Isolate high-quality cfDNA with high recovery and minimal genomic DNA contamination.
Isolate high-quality cfDNA with high recovery and minimal genomic DNA contamination.
Available pack size:
Available pack size:
Available pack size:
50 reactions
50 reactions
50 reactions
Built for sensitive
oncology workflows
Designed for the realities of oncology workflows
Optimized for oncology applications
Optimized for oncology applications
Optimized for oncology applications
Optimized for oncology applications
NGS
NGS
NGS
NGS
qPCR
qPCR
qPCR
qPCR
digital PCR
digital PCR
Optimized for liquid biopsy and MRD applications, supporting reliable detection of low-abundance ctDNA across
Optimized for liquid biopsy and MRD applications, supporting reliable detection of low-abundance ctDNA across
Optimized for liquid biopsy and MRD applications, supporting reliable detection of low-abundance ctDNA across
Efficient workflow
Efficient workflow
Efficient workflow
Efficient workflow
Bead-based purification reduces manual effort and supports automation, completing cfDNA extraction in ≈55 minutes.
Bead-based purification reduces manual effort and supports automation, completing cfDNA extraction in ≈55 minutes.
Bead-based purification reduces manual effort and supports automation, completing cfDNA extraction in ≈55 minutes.
Maximize yield from every sample
Maximize yield from every sample
Maximize yield from every sample
Maximize yield from every sample
Efficiently isolates cfDNA even from small plasma volumes, delivering consistent yields while preserving valuable sample material.
Efficiently isolates cfDNA even from small plasma volumes, delivering consistent yields while preserving valuable sample material.
Efficiently isolates cfDNA even from small plasma volumes, delivering consistent yields while preserving valuable sample material.
Enriched for tumor-relevant fragment sizes
Preferentially captures 150–200 bp cfDNA fragments, enriching tumor-derived DNA and improving detection sensitivity.
Preferentially captures 150–200 bp cfDNA fragments, enriching tumor-derived DNA and improving detection sensitivity.
Minimal genomic DNA contamination
Minimal genomic DNA contamination
Minimal genomic DNA contamination
Minimal genomic DNA contamination
Selective binding conditions help limit gDNA contamination.
Selective binding conditions help limit gDNA contamination.
Selective binding conditions help limit gDNA contamination.
Performance preview
Performance preview
Performance preview
Performance preview
Performance preview
RNA yield and purity datasets
RNA yield and purity datasets
RNA yield and purity datasets
RNA yield and purity datasets
RNA yield and purity datasets
From just four 10 µm FFPE curls, the kit delivers ~5,00 ng of RNA (Qubit) with excellent purity (A260/280: 1.9–2.1 & A260/230: 1.5–2.0). The high yield and quality make it ideal for demanding applications such as BCR-ABL testing and RNA-seq, ensuring reliable results and seamless downstream compatibility.
From just four 10 µm FFPE curls, the kit delivers ~5,00 ng of RNA (Qubit) with excellent purity (A260/280: 1.9–2.1 & A260/230: 1.5–2.0). The high yield and quality make it ideal for demanding applications such as BCR-ABL testing and RNA-seq, ensuring reliable results and seamless downstream compatibility.
From just four 10 µm FFPE curls, the kit delivers ~5,00 ng of RNA (Qubit) with excellent purity (A260/280: 1.9–2.1 & A260/230: 1.5–2.0). The high yield and quality make it ideal for demanding applications such as BCR-ABL testing and RNA-seq, ensuring reliable results and seamless downstream compatibility.
From just four 10 µm FFPE curls, the kit delivers ~5,00 ng of RNA (Qubit) with excellent purity (A260/280: 1.9–2.1 & A260/230: 1.5–2.0). The high yield and quality make it ideal for demanding applications such as BCR-ABL testing and RNA-seq, ensuring reliable results and seamless downstream compatibility.
Yield (ng)
Yield (ng)
A260/A280
A260/A280
A260/A230
A260/A230
Sample number
Qubit yield (ng)
500
1000
5000
10000
8
7
6
5
4
3
2
1
0.0
0.5
1.0
1.5
2.0
2.5
Purity ratio
Sample number
Qubit yield (ng)
500
1000
5000
10000
8
7
6
5
4
3
2
1
0.0
0.5
1.0
1.5
2.0
2.5
Purity ratio
Sample number
Qubit yield (ng)
500
1000
5000
10000
8
7
6
5
4
3
2
1
0.0
0.5
1.0
1.5
2.0
2.5
Purity ratio
RIN & DV200 values
RIN & DV200 values
RIN & DV200 values
RIN & DV200 values
RIN & DV200 values
DV200, the percentage of RNA fragments longer than 200 nucleotides, is a key metric for RNA-seq suitability (Illumina). Even with low-quality FFPE blocks, our kit consistently delivers high RNA yields that meet sequencing input requirements. While both DV200 and RIN values depend on the intrinsic quality of FFPE samples, our kit ensures reliable performance, with RIN values typically ranging from 1.9 to 3.8.
DV200, the percentage of RNA fragments longer than 200 nucleotides, is a key metric for RNA-seq suitability (Illumina). Even with low-quality FFPE blocks, our kit consistently delivers high RNA yields that meet sequencing input requirements. While both DV200 and RIN values depend on the intrinsic quality of FFPE samples, our kit ensures reliable performance, with RIN values typically ranging from 1.9 to 3.8.
DV200, the percentage of RNA fragments longer than 200 nucleotides, is a key metric for RNA-seq suitability (Illumina). Even with low-quality FFPE blocks, our kit consistently delivers high RNA yields that meet sequencing input requirements. While both DV200 and RIN values depend on the intrinsic quality of FFPE samples, our kit ensures reliable performance, with RIN values typically ranging from 1.9 to 3.8.
DV200, the percentage of RNA fragments longer than 200 nucleotides, is a key metric for RNA-seq suitability (Illumina). Even with low-quality FFPE blocks, our kit consistently delivers high RNA yields that meet sequencing input requirements. While both DV200 and RIN values depend on the intrinsic quality of FFPE samples, our kit ensures reliable performance, with RIN values typically ranging from 1.9 to 3.8.
Sample number
Sample number
Sample number
1
1
1
2
2
2
3
3
3
4
4
4
5
5
5
6
6
6
7
7
7
8
8
8
RIN
RIN
RIN
3.8
3.8
3.8
3.1
3.1
3.1
3.2
3.2
3.2
2.1
2.1
2.1
1.7
1.7
1.7
2.1
2.1
2.1
1.8
1.8
1.8
2.6
2.6
2.6
DV200 (%)
DV200 (%)
DV200 (%)
85.47
85.47
85.47
73.09
73.09
73.09
83.59
83.59
83.59
60.23
60.23
60.23
40.7
40.7
40.7
32.1
32.1
32.1
34.58
34.58
34.58
58.91
58.91
58.91
Optimized for
critical downstream assays
Gene expression profiling
Tumor subtype classification
Immune profiling (e.g., HER2+ vs. triple-negative breast cancer)
Biomarker discovery & validation
Transcriptome studies
RNA fusions & splice variants
Retrospective clinical research
Optimized for critical downstream assays
Gene expression profiling
Tumor subtype classification
Immune profiling (e.g., HER2+ vs. triple-negative breast cancer)
Biomarker discovery & validation
Linking RNA signatures to prognosis
Therapy response
Disease progression
Transcriptome studies
Global expression profiling
Whole-transcriptome RNA-seq for personalized oncology
RNA fusions & splice variants
Detect clinically relevant gene fusions
Characterize splice isoforms linked to cancer biology
Retrospective clinical research
Mining archived FFPE archives for relapse, survival, and long-term outcome correlations
Optimized for
critical downstream assays
Gene expression profiling
Tumor subtype classification
Immune profiling (e.g., HER2+ vs. triple-negative breast cancer)
Biomarker discovery & validation
Transcriptome studies
RNA fusions & splice variants
Retrospective clinical research
Optimized for critical downstream assays
Gene expression profiling
Tumor subtype classification
Immune profiling (e.g., HER2+ vs. triple-negative breast cancer)
Biomarker discovery & validation
Linking RNA signatures to prognosis
Therapy response
Disease progression
Transcriptome studies
Global expression profiling
Whole-transcriptome RNA-seq for personalized oncology
RNA fusions & splice variants
Detect clinically relevant gene fusions
Characterize splice isoforms linked to cancer biology
Retrospective clinical research
Mining archived FFPE archives for relapse, survival, and long-term outcome correlations
Optimized for
critical downstream assays
Gene expression profiling
Tumor subtype classification
Immune profiling (e.g., HER2+ vs. triple-negative breast cancer)
Biomarker discovery & validation
Transcriptome studies
RNA fusions & splice variants
Retrospective clinical research
Seamlessly integrates
with your lab needs
Seamlessly integrates
with your lab needs
Seamlessly integrates
with your lab needs
Seamlessly integrates
with your lab needs
Seamlessly integrates
with your lab needs
Effortlessly adapts to any lab workflow, from low-throughput manual research to high-throughput automated processing, without the need to redesign protocols.
Effortlessly adapts to any lab workflow, from low-throughput manual research to high-throughput automated processing, without the need to redesign protocols.
Effortlessly adapts to any lab workflow, from low-throughput manual research to high-throughput automated processing, without the need to redesign protocols.
Effortlessly adapts to any lab workflow, from low-throughput manual research to high-throughput automated processing, without the need to redesign protocols.
Technical specifications
Technical specifications
Technical specifications
FAQs
FAQs
Build reliable liquid
biopsy workflows
Discover how OncoSeek can support your MRD, liquid biopsy, and oncology research applications.
Discover how OncoSeek can support your MRD, liquid biopsy, and oncology research applications.
Discover how OncoSeek can support your MRD, liquid biopsy, and oncology research applications.
Discover how OncoSeek can support your MRD, liquid biopsy, and oncology research applications.